Takeda's Entyvio Beats Humira In Head-To-Head Ulcerative Colitis Trial
Takeda’s gut-selective biologic vedolizumab pushes ahead of other biologics in the race to make its mark in ulcerative colitis, a therapeutic sector targeted by numerous new investigational therapies.
You may also be interested in...
IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs
Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.
IBD Market Snapshot: Changes Ahead, But Current Biologics Are Formidable Competitors
The ulcerative colitis and Crohn’s disease landscapes may shift soon but new drugs will compete with entrenched blockbusters, including Humira, Stelara and Entyvio, with biosimilars on the way.
ICER 2020 Priorities Include Drugs For Ulcerative Colitis, NASH And Gene Therapies
The Institute for Clinical and Economic Review has a full agenda planned for 2020, starting with potential new oral drugs for migraine.